Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Glennie

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Cancer Cell|September 17, 2015
Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG FrameworkRienk Offringa, Martin J Glennie
Blood|October 11, 2003
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsMark S Cragg, Martin J Glennie
Blood|November 2, 2013
Neutrophils: "neu players" in antibody therapy?Stephen A Beers, Martin J Glennie
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
Agonistic CD40 antibodies and cancer therapyRobert H Vonderheide, Martin J Glennie
Cancer Research|August 17, 2005
Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cellsJamie Honeychurch, Martin J Glennie, Timothy M Illidge
Drug Discovery Today|June 24, 2003
Renaissance of cancer therapeutic antibodiesMartin J Glennie, Jan G J van de Winkel
Blood|December 26, 2009
Complement: help or hindrance?Stephen A Beers, Mark S Cragg, Martin J Glennie
Blood|January 15, 2016
Influence of immunoglobulin isotype on therapeutic antibody functionStephen A Beers, Martin J Glennie, Ann L White
Clinical Science (London, England : 1979)|July 13, 2006
Therapeutic potential of immunostimulatory monoclonal antibodiesJuliet C Gray, Peter W M Johnson, Martin J Glennie
Current Directions in Autoimmunity|November 27, 2004
The biology of CD20 and its potential as a target for mAb therapyMark S Cragg, Claire A Walshe, Andrey O Ivanov, et al.
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Cancer Cell|September 17, 2015
Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG FrameworkRienk Offringa, Martin J Glennie
Blood|October 11, 2003
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsMark S Cragg, Martin J Glennie
Blood|November 2, 2013
Neutrophils: "neu players" in antibody therapy?Stephen A Beers, Martin J Glennie
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
Agonistic CD40 antibodies and cancer therapyRobert H Vonderheide, Martin J Glennie
Cancer Research|August 17, 2005
Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cellsJamie Honeychurch, Martin J Glennie, Timothy M Illidge
Drug Discovery Today|June 24, 2003
Renaissance of cancer therapeutic antibodiesMartin J Glennie, Jan G J van de Winkel
Blood|December 26, 2009
Complement: help or hindrance?Stephen A Beers, Mark S Cragg, Martin J Glennie
Blood|January 15, 2016
Influence of immunoglobulin isotype on therapeutic antibody functionStephen A Beers, Martin J Glennie, Ann L White
Clinical Science (London, England : 1979)|July 13, 2006
Therapeutic potential of immunostimulatory monoclonal antibodiesJuliet C Gray, Peter W M Johnson, Martin J Glennie
Current Directions in Autoimmunity|November 27, 2004
The biology of CD20 and its potential as a target for mAb therapyMark S Cragg, Claire A Walshe, Andrey O Ivanov, et al.
Pageof 10